{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:25:22Z","timestamp":1781652322975,"version":"3.54.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T00:00:00Z","timestamp":1552953600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Amgen Europe"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Secondary hyperparathyroidism (SHPT) is frequent in haemodialysis (HD) patients. Oral cinacalcet-hydrochloride (HCl) decreases parathyroid hormone (PTH); however, real-life PTH data, according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, are still lacking. Our goal is to assess the percentage of cinacalcet-HCl-treated HD patients with controlled SHPT (PTH\u2009&amp;lt;9\u00d7 upper limit of the normal range) after 12\u2009months (M12) of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective observational study in HD patients with SHPT treated by cinacalcet-HCl between 2005 and 2015 and dialysed in seven French HD centres using the same database (Hemodial\u2122).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 1268 patients with a mean (standard deviation) follow-up of 21\u2009\u00b1\u200912\u2009months. Their mean dialysis vintage was 4.3\u2009\u00b1\u20095.6\u2009years. PTH values were available and exploitable at M12 in 50% of them (645 patients). Among these patients, 58.9% had controlled (mean PTH of 304\u2009\u00b1\u2009158\u2009pg\/mL) and 41.1% uncontrolled SHPT (mean PTH of 1084\u2009\u00b1\u2009543) at M12. At the baseline, patients with controlled SHPT were older (66\u2009\u00b1\u200915 versus 61\u2009\u00b1\u200917\u2009years), and had lower PTH (831\u2009\u00b1\u2009346 versus 1057\u2009\u00b1\u2009480\u2009pg\/mL) and calcaemia (2.18\u2009\u00b1\u20090.2 versus 2.22\u2009\u00b1\u20090.19\u2009mmol\/L) than uncontrolled patients. In multivariate analysis, these three factors still remained significantly associated with controlled SHPT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this real-life study, 41.1% of HD patients with SHPT treated with cinacalcet-HCl remained with a PTH above the KDIGO recommended target after 12 months of treatment. Apart from the possibility of non-compliance, the severity of SHPT appears to be a major factor determining the response to cinacalcet-HCl treatment, reinforcing the importance of treating SHPT at earlier stages.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfz021","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T09:06:07Z","timestamp":1549011967000},"page":"871-879","source":"Crossref","is-referenced-by-count":21,"title":["Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study"],"prefix":"10.1093","volume":"12","author":[{"given":"Jacques","family":"Rottembourg","sequence":"first","affiliation":[{"name":"Centre Diaverum, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[{"name":"Clinique du Landy, Saint Ouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Toledano","sequence":"additional","affiliation":[{"name":"AURA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gueutin","sequence":"additional","affiliation":[{"name":"AURA, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz","family":"Hamani","sequence":"additional","affiliation":[{"name":"H\u00f4pital priv\u00e9 Athis Mons, Athis-Mons, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Coldefy","sequence":"additional","affiliation":[{"name":"Polyclinique du Languedoc, Narbonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedia","family":"Hebibi","sequence":"additional","affiliation":[{"name":"H\u00f4pital priv\u00e9, Thiais, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guincestre","sequence":"additional","affiliation":[{"name":"Centre hospitalier de Roubaix, Roubaix, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Emery","sequence":"additional","affiliation":[{"name":"Cemka\/Eval, Bourg-la-Reine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"2020021105432785700_sfz021-B1","volume-title":"Endotext","author":"Drueke","year":"2000"},{"key":"2020021105432785700_sfz021-B2","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1172\/JCI117890","article-title":"Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia","volume":"95","author":"Arnold","year":"1995","journal-title":"J Clin Invest"},{"key":"2020021105432785700_sfz021-B3","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ndt\/gft514","article-title":"Is chronic kidney disease-mineral bone disorder (CKD\u2013MBD) really a syndrome?","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020021105432785700_sfz021-B4","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2020021105432785700_sfz021-B5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2020021105432785700_sfz021-B6","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1046\/j.1523-1755.63.s85.22.x","article-title":"Calcimimetic agents: review and perspectives","author":"Urena","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"2020021105432785700_sfz021-B7","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/ndt\/gfp144","article-title":"Cinacalcet and achievement of the NKF\/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice\u2014the ECHO observational study","volume":"24","author":"Urena","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2020021105432785700_sfz021-B8","first-page":"527","article-title":"[Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice\u2014the ECHO observational study: French experience]","volume":"8","author":"Urena","year":"2012","journal-title":"Nephrol Ther"},{"key":"2020021105432785700_sfz021-B9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1744-9987.2010.00843.x","article-title":"Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther","volume":"14","author":"Hirai","year":"2010","journal-title":"Apher Dial"},{"key":"2020021105432785700_sfz021-B10","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020021105432785700_sfz021-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/gfu015","article-title":"Drug adherence in chronic kidney diseases and dialysis","volume":"30","author":"Burnier","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2020021105432785700_sfz021-B12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.ajkd.2010.03.002","article-title":"Barriers to adult hemodialysis patients\u2019 self-management of oral medications","volume":"56","author":"Browne","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2020021105432785700_sfz021-B13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2369-14-153","article-title":"Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence","volume":"14","author":"Covic","year":"2013","journal-title":"BMC Nephrol"},{"key":"2020021105432785700_sfz021-B14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/2047-783X-14-5-185","article-title":"Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature","volume":"14","author":"Schmid","year":"2009","journal-title":"Eur J Med Res"},{"key":"2020021105432785700_sfz021-B15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nefro.2015.10.006","article-title":"Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism","volume":"36","author":"de Francisco","year":"2016","journal-title":"Nefrologia"},{"key":"2020021105432785700_sfz021-B16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"2020021105432785700_sfz021-B17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nephro.2014.08.002","article-title":"The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry","volume":"11","author":"Lassalle","year":"2015","journal-title":"Nephrol Ther"},{"key":"2020021105432785700_sfz021-B18","first-page":"1844","article-title":"Cinacalcet for cardiovascular disease in patients undergoing dialysis","volume":"368","author":"Chertow","year":"2013","journal-title":"N Engl J Med"},{"key":"2020021105432785700_sfz021-B19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2215\/CJN.07050714","article-title":"A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM)","volume":"10","author":"Wetmore","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020021105432785700_sfz021-B20","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020021105432785700_sfz021-B21","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ndt\/gfr531","article-title":"Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2020021105432785700_sfz021-B22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020021105432785700_sfz021-B23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2020021105432785700_sfz021-B24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","article-title":"Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism","volume":"28","author":"Urena-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2020021105432785700_sfz021-B25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nephro.2015.11.005","article-title":"[Changes in mineral and bone disorder management in a French cohort of hemodialysis patients between 2008 and 2012: The National Bone and Mineral Metabolism observatory (Photo-Graphe 2 and 3)]","volume":"12","author":"Pelletier","year":"2016","journal-title":"Nephrol Ther"},{"key":"2020021105432785700_sfz021-B26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.jrn.2006.01.011","article-title":"New therapies for uremic secondary hyperparathyroidism","volume":"16","author":"Torres","year":"2006","journal-title":"J Ren Nutr"},{"key":"2020021105432785700_sfz021-B27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1523-1755.2003.00064.x","article-title":"Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"2020021105432785700_sfz021-B28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-006-0116-0","article-title":"Medicine-related problems resulting in emergency department visits","volume":"62","author":"Baena","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"2020021105432785700_sfz021-B29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/12\/6\/871\/32429897\/sfz021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/12\/6\/871\/32429897\/sfz021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T05:44:52Z","timestamp":1581399892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/12\/6\/871\/5384509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,18]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz021","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,3,18]]}}}